Background Whether the two drug-eluting stents approved by the US Food and Drug
Administration—a sirolimus-eluting stent and a paclitaxel-eluting stent—are associated with …

Restenosis is a serious occurrence that can lead not only to recurrent angina and repeat
revascularisation but also to acute coronary syndromes. Drug-eluting stents revolutionised …

Background: Several treatment options exist for many conditions. Randomized trial evidence
on the relative merits of various options may be missing or biased. Purpose: To examine the …

PURPOSE: To report the midterm (≤ 1 year) angiographic and clinical outcomes of a
prospective study investigating the infrapopliteal application of paclitaxel-eluting stents …

Background Cigarette smoking strongly increases morbidity and mortality from
cardiovascular causes, but the relevance of smoking in patients treated with drug-eluting …

BACKGROUND: Drug-eluting stents have emerged as the favored device for percutaneous
coronary intervention. It is not clear if there are differences in the currently available drug …

Objective: Drug-eluting stents (DES) have reduced restenosis rates compared with bare-
metal stents. P27 and P53 play important roles in the signal transduction leading to …

This study was designed to compare the safety and efficacy of sirolimus-eluting stents
(SESs) to paclitaxel-eluting stents (PESs) in percutaneous intervention of saphenous vein …

Background Although long-term follow-up after sirolimus-eluting stent implantation shows a
sustained clinical benefit in several randomized and registered trials, little is known about …

Background Calcified coronary lesions carry the risk of suboptimal stent expansion,
subsequently leading to restenosis. The effectiveness of sirolimus-eluting stents (SES) for …